Adage Capital Partners Portfolio holdings
AUM
$59.3B
1-Year Return
26.26%
This Quarter Return
+10.56%
1 Year Return
+26.26%
3 Year Return
+130.73%
5 Year Return
+248.99%
10 Year Return
+658.76%
AUM
$46B
AUM Growth
+$1.4B
(+3.1%)
Cap. Flow
-$2.37B
Cap. Flow
% of AUM
-5.15%
Top 10 Holdings %
Top 10 Hldgs %
24.52%
Holding
1,017
New
103
Increased
238
Reduced
409
Closed
154
Top Buys
| 1 |
Boeing
BA
|
$184M |
| 2 |
Domino's
DPZ
|
$182M |
| 3 |
Lockheed Martin
LMT
|
$139M |
| 4 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$132M |
| 5 |
VMW
VMware, Inc
VMW
|
$92.3M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$320M |
| 2 |
Chipotle Mexican Grill
CMG
|
$226M |
| 3 |
Exxon Mobil
XOM
|
$138M |
| 4 |
SJR
Shaw Communications Inc.
SJR
|
$137M |
| 5 |
Dover
DOV
|
$137M |
Sector Composition
| 1 | Technology | 26.41% |
| 2 | Healthcare | 17.16% |
| 3 | Financials | 11.58% |
| 4 | Consumer Discretionary | 10.02% |
| 5 | Industrials | 9.45% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
726
DT Midstream
DTM
$10.7B
| $2.48M | 0.01% |
50,000
| – | – |
|
727
Humana
HUM
$37B
| $2.48M | 0.01% |
5,540
-168,900
| -97% | -$75.5M |
|
728
Alpha Metallurgical Resources
AMR
$1.91B
| $2.47M | 0.01% |
+15,000
| New | +$2.47M |
|
729
Intellia Therapeutics
NTLA
$1.29B
| $2.45M | 0.01% |
60,000
-3,000
| -5% | -$122K |
|
730
Charles River Laboratories
CRL
$8.07B
| $2.34M | 0.01% |
11,148
+3,343
| +43% | +$703K |
|
731
Manchester United
MANU
$2.71B
| $2.34M | 0.01% |
95,853
-54,263
| -36% | -$1.32M |
|
732
News Corp Class B
NWS
$18.8B
| $2.31M | 0.01% |
117,034
-1,000
| -0.8% | -$19.7K |
|
733
Ovintiv
OVV
$10.6B
| $2.28M | 0.01% |
60,000
-1,084,949
| -95% | -$41.3M |
|
|
SYRS
734
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $2.27M | ﹤0.01% |
721,914
| – | – |
|
735
Novavax
NVAX
$1.28B
| $2.23M | ﹤0.01% |
+300,000
| New | +$2.23M |
|
736
Olema Pharmaceuticals
OLMA
$570M
| $2.09M | ﹤0.01% |
231,433
-188,567
| -45% | -$1.7M |
|
|
BPMC
737
DELISTED
Blueprint Medicines
BPMC
| $2.08M | ﹤0.01% |
+32,903
| New | +$2.08M |
|
738
Larimar Therapeutics
LRMR
$337M
| $2.04M | ﹤0.01% |
651,680
| – | – |
|
739
AGNC Investment
AGNC
$10.8B
| $2.03M | ﹤0.01% |
+200,000
| New | +$2.03M |
|
740
Warrior Met Coal
HCC
$3.19B
| $1.95M | ﹤0.01% |
+50,000
| New | +$1.95M |
|
|
SMAR
741
DELISTED
Smartsheet Inc.
SMAR
| $1.91M | ﹤0.01% |
50,000
| – | – |
|
742
Immuneering
IMRX
$229M
| $1.77M | ﹤0.01% |
175,000
-30,000
| -15% | -$304K |
|
743
Biomea Fusion
BMEA
$114M
| $1.76M | ﹤0.01% |
80,000
-1,653,251
| -95% | -$36.3M |
|
744
Waters Corp
WAT
$18.2B
| $1.72M | ﹤0.01% |
6,466
-32,999
| -84% | -$8.8M |
|
745
W.P. Carey
WPC
$14.9B
| $1.69M | ﹤0.01% |
+25,525
| New | +$1.69M |
|
746
Lantheus
LNTH
$3.72B
| $1.68M | ﹤0.01% |
+20,000
| New | +$1.68M |
|
747
Mersana Therapeutics
MRSN
$34M
| $1.65M | ﹤0.01% |
+20,000
| New | +$1.65M |
|
748
Wayfair
W
$11.6B
| $1.63M | ﹤0.01% |
+25,000
| New | +$1.63M |
|
749
Darling Ingredients
DAR
$5.07B
| $1.59M | ﹤0.01% |
+25,000
| New | +$1.59M |
|
750
AAR Corp
AIR
$2.71B
| $1.56M | ﹤0.01% |
27,033
| – | – |
|